Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

NCT06523699 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Recombinant glycosylated human interleukin-7
DRUG: Melphalan
PROCEDURE: Autologous hematopoietic cell transplant

Sponsor

Washington University School of Medicine

Collaborators

[object Object]